This article is more than 5 years old. Information may no longer be current.
Brinzolamide may be most effective for IOP reduction after cataract surgery
Brinzolamide provided the best short-term IOP reduction after cataract surgery compared with travoprost or timolol, according to a study.
The randomized clinical study included 165 eyes of 165 patients with primary open-angle glaucoma or pseudoexfoliation glaucoma scheduled for phacoemulsification. Patients received travoprost, timolol or brinzolamide after cataract surgery, and IOP was measured 1 hour preoperatively, at the end of surgery, and at 2, 4, 6, 8 and 24 hours postoperatively.
At the end of surgery, mean IOP was 19.15 mm Hg in the travoprost eyes, 18.39 mm Hg in the timolol eyes and 18.26 mm Hg in the brinzolamide eyes. The mean IOP increased significantly between 4 and 8 hours in all groups and then decreased at 24 hours postoperatively in all groups, (P < .0001) to 16.6 mm Hg in travoprost eyes, 15.49 mm Hg in timolol eyes and 15.28 mm Hg in brinzolamide eyes. At 4, 6 and 8 hours, mean IOP of brinzolamide eyes was significantly lower than in the other two groups (P .0374).
“Additionally, the incidence of a marked IOP increase was significantly lower in eyes that received brinzolamide than in eyes that received travoprost or timolol. These findings suggest that brinzolamide more effectively reduces the short-term IOP elevation than timolol or travoprost in eyes with glaucoma,” the researchers wrote. – by Robert Linnehan
Disclosures: The authors report no relevant financial disclosures.